NASDAQ$RNA

Atrium Therapeutics Inc · Q1 2026 earnings

Q1 2026 earnings ·

Briefing

Atrium Therapeutics Inc reported its financial results for the first quarter ended March 31, 2026 following its spin-off from Avidity Biosciences.

Atrium Therapeutics Inc, a preclinical-stage biopharmaceutical company developing RNA therapeutics for cardiomyopathies, reported collaboration revenue of $19.6 million for Q1 2026, primarily from its BMS partnership including a $15 million milestone. The company recorded a net loss of $16.6 million and ended the quarter with $267.8 million in cash and cash equivalents after receiving approximately $270 million in capitalization upon its February 26, 2026 spin-off. Operating expenses increased significantly due to higher R&D and G&A costs as the company transitioned to an independent public entity.

  • Recognized $19.6 million in collaboration revenue, including a $15 million milestone payment from the BMS Collaboration Agreement for delivery of a development candidate.
  • Reported a net loss of $16.6 million and basic/diluted EPS of $(0.97), reflecting increased operating expenses post-spin-off.
  • Maintained a strong liquidity position with $267.8 million in cash and cash equivalents and total assets of $292.4 million.
  • Advanced preclinical programs with plans to file an IND for ATR 1072 in the second half of 2026 and for ATR 1086 in 2027.

Headline financials

Total Revenue

$19.6M

Previous: $1.57M+1148.3%
EPS (adj)

-$0.97

Previous: $0.90-207.8%
Collaboration Revenue

$19.6M

No prior period
R&D Expense

$16.7M

No prior period
G&A Expense

$20.3M

No prior period
Capital Expenditures

-$2.1M

Previous: -$3.75M+44.1%
Free Cash Flow

-$33.2M

Previous: -$120M+72.2%
Net Income

-$16.6M

Previous: -$116M+85.6%
Operating Income

-$17.3M

Previous: -$132M+86.9%
Cash & Equivalents

$268M

No prior period
Total Assets

$292M

No prior period

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$19.6M

Q1 2026+1,148.3%vs Q1 2025
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Forward guidance

The company plans to file an IND for ATR 1072 in the second half of 2026 and for ATR 1086 in 2027 while advancing its precision cardiology pipeline.

Tailwinds

  • Strong cash position of $267.8 million expected to fund operations for at least 12 months
  • Achievement of $15 million milestone under BMS collaboration
  • Robust preclinical data supporting advancement of lead candidates

Headwinds

  • Increased operating expenses following spin-off and transition to standalone operations
  • Continued net losses expected as development programs advance
  • Reliance on third parties for manufacturing and clinical activities

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro